BioCentury
ARTICLE | Company News

Sanofi shies away from neuro gene therapy programs

June 17, 2019 11:33 PM UTC

Changes to two partnerships this year suggest Sanofi is paring down the disease areas in which it wants to deploy gene therapy.

The latest came on Monday, when Voyager Therapeutics Inc. (NASDAQ:VYGR) said it and Sanofi (Euronext:SAN; NASDAQ:SNY) agreed to terminate Sanofi's ex-U.S. option rights to Friedreich ataxia gene therapy VY-FXN01 and to Huntington disease gene therapy VY-HTT01, as well as its option to U.S. co-commercialization rights to VY-HTT01. The partners also agreed to terminate a collaboration to develop gene therapies for spinal muscular atrophy (SMA)...